Imaging CXCR4-related diseases using PET/CT
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
This study is testing a new type of imaging to see if it can better identify and track diseases related to CXCR4 in patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06690736 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with CXCR4-related diseases. Participants will undergo PET/CT imaging to assess the uptake of the tracer in lesions, with results analyzed for sensitivity, specificity, and accuracy. The goal is to determine how well this imaging technique can identify and monitor these diseases.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected or confirmed untreated lymphoproliferative and other CXCR4-related diseases.
Not a fit: Patients who are pregnant, breastfeeding, or have a known allergy to Pentixafor may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could improve the diagnosis and monitoring of CXCR4-related diseases, leading to better patient outcomes.
How similar studies have performed: Other studies have shown promising results with similar imaging approaches, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients * 18F-FDG PET/CT within two weeks * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor
Where this trial is running
Tianjin, Tianjin Municipality
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.